Advertisement
Collaboration › Details
Standard BioTools–UBS: investor conference, 202408 supply service Standard BioTech participates in UBS Genomic Medicine Summit
Period | 2024-08-14 | |
Partner, 1st | Standard BioTools Inc. (Nasdaq: LAB) | |
Group | Standard BioTools (Group) | |
Partner, 2nd | UBS Securities LLC | |
Group | UBS (Group) | |
Product | UBS MedTech, Tools and Genomics Summit 2024 Dana Point | |
Product 2 | laboratory equipment and instruments | |
Person | Egholm, Michael (Fluidigm 2022Q2– CEO before Danaher Life Sciences + Pall + 454 Life Sciences + Molecular Staging) | |
Person 2 | Holmes, David (Gilmartin Group 202408) | |
Standard BioTools Inc.. (8/6/24). "Press Release: Standard BioTools to Participate in Upcoming Investor Conferences". South San Francisco, CA.
Standard BioTools Inc. (Nasdaq:LAB), today announced that its management team will participate in the following investor conferences in the month of August:
> Canaccord Genuity 44th Annual Growth Conference on August 13th, 2024
President and CEO, Michael Egholm, PhD, will participate in a fireside chat on Tuesday, August 13, 2024, at 9:00 a.m. ET
> UBS Genomic Medicine Summit on August 14th, 2024
President and CEO, Michael Egholm, PhD, will participate in a panel discussion:
Expanding Horizons - Spatial and Beyond on Wednesday, August 14, 2024, at 2:00 p.m. PT
Available presentations will be webcast live and available on the Investor Relations page of the Company’s website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms. Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners.
©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact:
David Holmes
Gilmartin Group LLC
(332) 330-1031
ir@standardbio.com
Record changed: 2024-08-13 |
Advertisement
More documents for Standard BioTools (Group)
- [1] Standard BioTools Inc.. (8/6/24). "Press Release: Standard BioTools to Participate in Upcoming Investor Conferences". South San Francisco, CA....
- [2] Standard BioTools Inc.. (1/5/24). "Press Release: Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools". South San Francisco, CA & Boulder, CO....
- [3] Standard BioTools Inc.. (10/4/23). "Press Release: Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools". South San Francisco, CA & Boulder, CO....
- [4] Fluidigm Corporation. (4/4/22). "Press Release: Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.". South San Francisco, CA....
- [5] Fluidigm Corporation. (4/1/22). "Press Release: Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion". South San Francisco, CA....
- [6] Fluidigm Corporation. (3/28/22). "Press Release: Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution". South San Francisco, CA....
- [7] Fluidigm Corporation. (1/24/22). "Press Release: Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc.". South San Francisco, CA....
- [8] SomaLogic, Inc.. (12/2/21). "Press Release: SomaLogic Announces Appointment of Steven Mermelstein as Senior Vice President of Corporate Strategy, Development and Mergers and Acquisitions". Boulder, CO....
- [9] Fluidigm Corporation. (9/2/21). "Press Release: Fluidigm to Participate in the Cantor Virtual Global Healthcare Conference". South San Francisco, CA....
- [10] SomaLogic, Inc.. (12/22/20). "Press Release: SomaLogic Adds $81M to Series A Financing Totaling $214M". Boulder, CO....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top